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Abstract
Background: Kaposi's sarcoma (KS) associated herpesvirus (KSHV) is the etiological agent of KS,
a neoplasm characterized by proliferating spindle cells, extensive neoangiogenesis and a prominent
inflammatory infiltrate. Infection of blood vascular endothelial cells with KSHV in vitro results in
their spindle cell transformation, which is accompanied by increased expression of inflammatory
chemokines and cytokines, and acquisition of lymphatic endothelial markers. Mimicking the effect
of viral infection, ectopic expression of KSHV-encoded latent protein vFLIP K13 is sufficient to
induce spindle transformation of vascular endothelial cells. However, the effect of K13 expression
on global gene expression and induction of lymphatic endothelial markers in vascular endothelial
cells has not been studied.
Methods: We used gene array analysis to determine change in global gene expression induced by
K13 in human vascular endothelial cells (HUVECs). Results of microarray analysis were validated
by quantitative RT-PCR, immunoblotting and a multiplex cytokine array.
Results: K13 affected the expression of several genes whose expression is known to be modulated
by KSHV infection, including genes involved in immune and inflammatory responses, anti-apoptosis,
stress response, and angiogenesis. The NF-κB pathway was the major signaling pathway affected by
K13 expression, and genetic and pharmacological inhibitors of this pathway effectively blocked
K13-induced transcriptional activation of the promoter of CXCL10, one of the chemokines whose
expression was highly upregulated by K13. However, K13, failed to induce expression of lymphatic
markers in blood vascular endothelial cells.
Conclusion: While K13 may account for change in the expression of a majority of genes observed
following KSHV infection, it is not sufficient for inducing lymphatic reprogramming of blood
vascular endothelial cells.
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Background
Infection with Kaposi's Sarcoma (KS)-associated herpesvi-
rus (KSHV), also known as the Human herpesvirus 8
(HHV8), has been linked to the development of Kaposi's
sarcoma (KS), primary effusion lymphoma and multicen-
tric Castleman's disease [1] KS is a highly vascular tumor
that is induced by the infection of vascular or lymphatic
endothelial cells with KSHV and is characterized by the
presence of distinctive proliferating spindle-like cells,
prominent neoangiogenesis and infiltration by inflamma-
tory cells [2,3]. The spindle cells not only represent the
tumor cells in the KS lesion, but also produce a number of
proinflammatory and angiogenic factors that drive the
growth of the lesion [3]. Latent infection of both micro-
and macro-vascular endothelial cells with KSHV in vitro
makes them acquire a spindle cell phenotype, which is
accompanied by increased expression of a number of
genes involved in the regulation of immune and inflam-
matory responses, cellular stress, apoptosis and angiogen-
esis [4-6]. Interestingly, KSHV infection of blood vascular
endothelial cells also upregulates the expression of several
of lymphatic markers, such as PROX-1, VEGFR-1, Podo-
planin and XLKD1/LYVE1, which has led to the sugges-
tion that KSHV infection results in lymphatic
reprogramming of vascular endothelial cells [7-9].
The KSHV-encoded K13 protein is one of the few proteins
to be expressed in latently-infected spindle cells. Although
originally classified as a viral FLICE inhibitory protein
(vFLIP), K13 was subsequently shown to be a potent acti-
vator of the NF-κB pathway [10-12], and to use this path-
way to promote cellular survival, proliferation,
transformation, cytokine secretion and KSHV latency [13-
20]. Ectopic expression of K13 in human vascular
endothelial cells is sufficient to transform them into spin-
dle cells, which is accompanied by the upregulated expres-
sion of several proinflammatory cytokines and adhesion
molecules known to be induced in KSHV-infected vascu-
lar endothelial cells [21,22]. However, the effect of K13 on
global gene expression in vascular endothelial cells has
not been studied. It is also not clear whether ectopic
expression of K13 in vascular endothelial cells, in the
absence of other KSHV latent genes, is sufficient for induc-
ing the changes in gene expression observed following
infection with KSHV. To address these questions, we have
examined the effect of ectopic K13 expression on global
gene expression in human vascular endothelial cells
(HUVECs). Our results indicate that K13 may account for
change in the expression of a significant proportion of
genes observed following KSHV infection. However, in
contrast to KSHV infection, ectopic expression of K13 is
incapable of inducing the expression of lymphatic
endothelial markers.
Methods
Cells used in this study
Human Umbilical Vein Endothelial Cells (HUVECs) were
purchased from Cambrex (East Rutherford, NJ) and were
grown in EMB medium containing 10% FBS (fetal bovine
serum) and supplemented with the bullet kit. Cells were
used for experiments at passages 2 to 6. HUVECs stably
transduced with an MSCVneo vector expressing a 4-
Hydroxytamoxifen (4OHT)-inducible K13-ERTAM  con-
struct were selected in G418 and have been described pre-
viously [21]. These cells were maintained under G418
selection for several passages prior to being used in the
experiments to ensure that the experiments were con-
ducted with stably transduced cells. An independent pop-
ulation of HUVECs stably transduced with a MSCV-hygro
vector encoding the K13-ERTAM fusion construct were also
generated and used to confirm the results of the microar-
ray analysis.
Gene chip human array
We used the human genome HGU-133 plus 2.0 arrays
(Affymatrix, Santa Clara, CA), an oligonucleotide-probe
based gene array chip containing ~50,000 transcripts,
which provides a comprehensive coverage of the whole
human genome.
RNA isolation and hybridization to oligonucleotide arrays
HUVECs stably expressing empty vectors (MSCVneo and
MSCV-hygro) or K13-ERTAM-encoding constructs were
treated with 4OHT (50 nM) or solvent for 48 h. Total RNA
was isolated using Qiagen RNeasy kit (Qiagen, Valencia,
CA). Ten micrograms of total RNA was used to synthesize
cDNA. T7 promoter introduced during the first strand syn-
thesis was then used to direct cRNA synthesis, which was
labeled with biotinylated deoxynucleotide triphosphate,
following the manufacturer's protocol (Affymatrix, San
Diego, California). After fragmentation, the biotinylated
cRNA was hybridized to the gene chip array at 45°C for 16
h. The chip was washed, stained with phycoerytherin-
streptavidin, and scanned with the Gene Chip Scanner
3000. After background correction, preliminary data anal-
ysis was done in the Microarray Suite 5.0 software (MAS
5.0, Stratagene, La Jolla, CA). For primary analysis we used
PLIER as recommended in the work flow of software Gene
Spring GX10.0 (Agilent Technologies, Santa. Clara).
Gene array data analysis
Fluorescence intensities were uploaded to the Array Assist
6.5 and Gene Spring GX10.0 (Agilent Technologies, Santa
Clara) software. Data was normalized by quantitative nor-
malization, and then transferred logarithmically for fur-
ther analysis to determine changes in a particular gene
induced by K13. In order to compare the changes in geneBMC Medical Genomics 2009, 2:50 http://www.biomedcentral.com/1755-8794/2/50
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expression, the data was further normalized by using the
50 RFU fluorescence value as threshold, and statistical
analysis showing fold changes was determined (p ≤ 0.05).
The microarray experiment design, setup, and data have
been deposited in National Center for Biotechnology
Information's Gene Expression Omnibus and are accessi-
ble through GEO series accession number GSE16051.
Luciferase reporter assay
A luciferase reporter plasmid containing the CXCL10/IP-
10 promoter (pGL3IP-10) was kindly provided by Dr.
Dan Muruve (University of Calgary). Expression con-
structs for K13, K13-58AAA and MC159 have been
described previously [14]. 293T cells were transfected in a
24-well plate with various test plasmids along with the
CXCL10 luciferase reporter constructs (50 ng/well) and a
pRSV/LacZ (β-galactosidase) reporter construct (75 ng/
well), as described previously [10]. Cells were lysed 2436
h later, and cell extracts were used to measure firefly luci-
ferase and β-galactosidase activities, respectively. Luci-
ferase activity was normalized by the β-galactosidase
activity to control for differences in transfection efficiency.
Western blot
Western blot analysis was performed as described previ-
ously [21]. Primary antibody dilutions used in these
experiments were Flag (1:5000; Sigma, St. Louis), COX2
(1:1000; Cayman Chemicals, Michigan), β-actin (1:5000;
Sigma, St. Louis), IκB-α (1:2000: Santa Cruz, Santa Cruz,
CA) and Tubulin ((1:1000; Sigma, St. Louis).
Network, gene ontology and canonical pathways analysis
Genes, which qualified in the stringent statistical tests,
were used for gene ontology and pathway analysis.
Expression data sets containing gene identifier and their
corresponding expression values, as fold-changes, were
uploaded as a tab-delimited text file to the Ingenuity path-
way Analysis (IPA) software (Ingenuity systems, Moun-
tain view, CA). Genes, which mapped to the ingenuity
pathway database, were categorized based on molecular
functions, gene ontology and biological processes. Each
class was grouped based on their p-value. The identified
genes named as focused genes were also mapped to
genetic networks in the IPA database and ranked by score.
The calculated probability score represented whether a
collection of genes in a network could be found by chance
alone.
mRNA expression assay by quantitative reverse transcript-
polymerase chain reaction (qRT-PCR)
cDNA was synthesized from RNA samples by PCR RNA
core kit (Applied Biosystems, Bedford, MA). Real time
quantitative reverse transcript-polymerase chain reaction
(qRT-PCR) with SYBER Green, using gene-specific PCR
primers, was performed to verify the microarray data.
Eleven genes were selected randomly and the primers
used to amplify each gene are listed in the Additional File-
1. Samples were run in triplicate, and PCR was performed
by an ABI 7700 thermocycler (Applied Biosystems, Bed-
ford, MA). Expression of multiple house keeping genes
(GNB, β-actin, GAPDH and tubulin) were simultaneously
determined for normalization, following the geNorm
method [23]. A linear regression analysis was performed
and the coefficient of variation was calculated to assess a
correlation between the RT-PCR and gene array results of
these 11 randomly selected genes.
Multiplex analysis for cytokines and chemokines affected 
by K13
The LabMAP technology (Luminex) combines the princi-
ple of a sandwich immunoassay with the fluorescent-
bead-based technology. A Luminex-based Multiplexed
assay was purchased from Biosource International
(Camarillo, CA) and used to measure the presence of
cytokines and chemokines in culture supernatants of
HUVEC-K13-ERTAM that had been mock-treated or treated
with 4OHT for 48 h. For comparison, supernatant from
HUVECs infected with KSHV for 48 h was included.
Results
Induction of host gene expression by K13
In our previous work, we used retroviral-mediated gene
transfer to generate human umbilical endothelial cells
(HUVECs) with stable expression of a K13-ERTAM fusion
construct in which the K13 cDNA is fused in-frame to the
ligand-binding domain of a mutated estrogen receptor
[21]. The mutated estrogen receptor does not bind to its
physiological ligand estrogen, but binds with very high
affinity to the synthetic ligand 4OHT (4-hydroxyta-
moxifen) and regulates the activity of K13 in a 4OHT-
dependent manner [21]. In the absence of 4OHT treat-
ment, the K13-ERTAM-HUVECs maintain their cobble-
stone appearance and are indistinguishable from the
empty vector-expressing cells in their growth characteris-
tics. However, these cells acquire spindle morphology
within 24 h of induction by 4OHT treatment, thus mim-
icking the effect of KSHV infection [21].
To comprehensively identify the spectrum of genes
induced by K13 expression, HUVECs with long-term sta-
ble expression of empty vector (MSCV) and K13-ERTAM
were plated in parallel cultures. Each group of cells was
then mock treated or treated with 4OHT for 48 h and RNA
was harvested from all plates simultaneously. The RNA
was then quantified and subjected to high density oligo-
nucleotide microarray analysis using the Affymetrix HG-
U133 plus 2 gene array representing ~50,000 annotated
transcripts.BMC Medical Genomics 2009, 2:50 http://www.biomedcentral.com/1755-8794/2/50
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We used several well established data mining tools to ana-
lyze the microarray data. The change in gene expression,
expressed as fluorescence, was first examined by scatter
plot analysis. In the control vector (MSCV)-expressing
HUVECs, the fluorescence ratios of most of the genes with
and without 4OHT treatment remained close to 1 or
changed slightly (≤2), suggesting that 4OHT by itself did
not have significant effect on gene expression (Figure 1a).
In contrast, in the K13-ERTAM-expressing HUVECs, the flu-
orescence ratios of a significant proportion of genes was
changed more than 2 fold following 4OHT treatment
(Figure 1b).
In order to validate our gene array data, 11 genes were ran-
domly chosen (COX2/PTGS2, CSF2, CXCL10, CXCL3,
hIL8, hIL6, IGFB5, RANTES/CCL5, SOD2, and VCAM-1)
and their expression was measured by real time RT-PCR
(qRT-PCR). This group included both up- and down-reg-
ulated genes. To our satisfaction, there was a good corre-
lation between the qRT-PCR and gene array data (R2 =
0.845) (Figure 2a and 2b). To correlate the gene array and
qRT-PCR detected transcription changes with protein lev-
els, we analyzed the expression levels of COX2/PTGS2
protein by immunoblot and confirmed its strong induc-
tion in K13-ERTAM-expressing HUVECs following 4OHT
treatment (Figure 2c). Additional validation of microarray
data at the protein level was obtained by a multiplex
cytokine assay (see below). Taken collectively, there was a
good correlation between array and other means of target
verification, thereby validating our methodology and
analysis.
Identification of genes differentially affected by K13
In order to identify genes that were differentially affected
by 4OHT treatment in the HUVEC-K13-ERTAM, the gene
array data was uploaded to Array Assist® gene expression
software. It was mean shift normalized and primary anal-
ysis was performed using PLIER, as recommended in the
workflow of the software. Only 174 genes, which showed
more than two fold difference in 4OHT-treated over
mock-treated cells (p < 0.01), met the stringency of this
statistical analysis. Of these 174 genes, 123 genes were
upregulated, whereas 51 genes were down-regulated. A list
of 50 most upregulated and 15 most down-regulated
genes are provided in Table 1 and a complete list of all
K13 affected genes is provided in Additional File 2. A sim-
ilar effect of K13 induction on global gene expression was
observed in the HUVECs stably transduced with the
MSCV hygro-K13-ERTAM construct (data not shown).
Identification of K13-modulated biologically relevant 
networks
In order to find biological interactions among these 174
genes, pathway analysis was carried out by the Ingenuity
Pathway Analysis (IPA) software tool. It was found that
156 of the 174 genes mapped to genetic networks as
defined by the IPA tool (Additional File 3). These net-
works are based on known functional interactions
between the gene products as described in the literature.
The tool then associates these networks with known bio-
logical pathways. Eight networks were affected signifi-
cantly by K13 expression as they had more of the
identified genes present than would be expected by
chance (score of >20). These networks were associated
with important cancer-related cellular events such as cell
death, cellular growth and proliferation, cellular move-
ment, immune response, inflammatory diseases, immune
responses and hematological diseases (Additional File 3).
The pathway (#1), which is associated with cell death,
inflammatory diseases and immunological diseases, was
identified as the most significantly influenced by K13.
This pathway contained 27 genes with a highly significant
score of 51. Consistent with the known ability of K13 to
activate the NF-κB pathway, the IPA identified the NF-κB
pathway as a key pathway linked to the gene networks per-
turbed by K13 activity in HUVECs (Additional File 4).
Additionally, pathway analysis by Gene Spring GX10
identified NF-κB as the major pathway linked to K13
activity (p < 0.05).
We next performed Gene Ontology (GO) analysis on the
microarray data. The GO analysis inquires into the func-
tions of all significantly affected genes regardless of their
(a & b). Scatter plot analysis of genes induced by 4OHT  treatment in the control vector and K13-ERTAM-expressing  HUVECs Figure 1
(a & b). Scatter plot analysis of genes induced by 
4OHT treatment in the control vector and K13-
ERTAM-expressing HUVECs. Each point on the scatter 
plots represents the expression of an individual mRNA mes-
sage, as determined by units of fluorescent intensity, in 
untreated cells (x axis) plotted against its expression after 
4OHT treatment (y axis). The lines on scatter plot indicate 
the 2-fold boundaries used for selecting genes with differen-
tial expression. The 4OHT-regulated genes fall outside of 
these lines. Only one of the two experiments is presented; 
similar results were obtained with the duplicate experiment.BMC Medical Genomics 2009, 2:50 http://www.biomedcentral.com/1755-8794/2/50
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Validation of gene expression array data by qRT-PCR and western blotting Figure 2
Validation of gene expression array data by qRT-PCR and western blotting. (a). Eleven genes were randomly picked 
and their relative mRNA levels in the mock- and 4OHT- treated vector and K13-ERTAM expressing HUVECs were examined 
using real-time RT-PCR. The two different methods, the microarrays and the RT-PCR, show excellent qualitative agreement. 
(b). Linear regression analysis shows excellent correlation between the qRT-PCR and microarray data with a coefficient of var-
iation (R2) of 0.845. (c). Western blot analysis confirms induction of COX-2/PTGS2 upon treatment of K13-ERTAM cells with 
4OHT. Tubulin blot shows equal protein loading.BMC Medical Genomics 2009, 2:50 http://www.biomedcentral.com/1755-8794/2/50
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Table 1: List of most differentially regulated genes in 4OHT-treated K13 ER-HUVECs.
Gene Name Gene Entrez Gene Fold Change
Up-regulated genes
1 chemokine (C-C motif) ligand 2 CCL2 6347 71.4
2 ubiquitin D UBD 10537 58.4
3 chemokine (C-C motif) ligand 20 CCL20 6364 53.1
4 chemokine (C-C motif) ligand 5 CCL5 6352 48.3
5 chemokine (C-X-C motif) ligand 10 CXCL10 3627 47.7
6 vascular cell adhesion molecule 1 VCAM1 7412 46.0
7 selectin E (endothelial adhesion molecule 1) SELE 6401 35.4
8 superoxide dismutase 2, mitochondrial SOD2 6648 35.2
9 chemokine (C-X-C motif) ligand 3 CXCL3 2921 33.8
10 chemokine (C-X-C motif) ligand 2 CXCL2 2920 32.2
11 interleukin 8 IL8 3576 31.5
12 chromosome 15 open reading frame 48 C15orf48 84419 29.6
13 solute carrier family 7 (cationic amino acid transporter) SLC7A2 6542 23.2
14 chemokine (C-X3-C motif) ligand 1 CX3CL1 6376 22.3
15 intercellular adhesion molecule 1 (CD54) ICAM1 3383 22.2
16 tumor necrosis factor, alpha-induced protein 6 TNFAIP6 7130 21.2
17 interleukin 6 (interferon, beta 2) IL6 3569 21.1
18 colony stimulating factor 2 (granulocyte-macrophage) CSF2 1437 15.1
19 interferon stimulated exonuclease gene 20 kDa ISG20 3669 13.6
20 chemokine (C-X-C motif) ligand 5 CXCL5 6374 13.0
21 laminin, gamma 2 LAMC2 3918 12.7
22 tumor necrosis factor, alpha-induced protein 3 TNFAIP3 7128 12.5
23 matrix metallopeptidase 10 (stromelysin 2) MMP10 4319 11.5
24 tumor necrosis factor, alpha-induced protein 2 TNFAIP2 7127 11.3
25 Epstein-Barr virus induced gene 3 EBI3 10148 9.8
26 tumor necrosis factor (ligand) superfamily, member 13b TNFSF13B 10673 9.6
27 phospholipase A1 member A PLA1A 51365 9.4
28 GTP cyclohydrolase 1 (dopa-responsive dystonia) GCH1 2643 9.0
29 nuclear factor of kappa light polypeptide gene enhancer, alpha NFKBIA 4792 8.3
30 proteasome (prosome, macropain) subunit, beta type, 9 PSMB9 5698 7.9
31 Chemokine (C-X-C motif) 1 CXCl1 2919 7.7
32 histone cluster 2, H2aa3 HIST2 723790 7.5
33 HLA-G histocompatibility antigen, class I, G HLA-G 3135 7.2
34 hydroxysteroid (11-beta) dehydrogenase 1 HSD11B1 3290 7.2
35 chemokine (C-X-C motif) receptor 7 CXCR7 57007 7.0
36 major histocompatibility complex, class I, B HLA-B 3106 6.3
37 nuclear receptor coactivator 7 NCOA7 135112 6.1
38 myxovirus (influenza virus) resistance 2 (mouse) MX2 4600 5.8
39 radical S-adenosyl methionine domain containing 2 RSAD2 91543 5.6
40 TNFAIP3 interacting protein 1 TNIP1 10318 5.5
41 tissue factor pathway inhibitor 2 TFPI2 7980 5.4
42 interleukin 32 IL32 9235 5.3
43 Nibrin NBN 4683 5.2
44 receptor (chemosensory) transporter protein 4 RTP4 64108 5.2
45 baculoviral IAP repeat-containing 3 BIRC3 330 5.1
46 interleukin 7 receptor /// interleukin 7 receptor IL7R 3575 5.0
47 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) TAP1 6890 5.0
48 papilin, proteoglycan-like sulfated glycoprotein PAPLN 89932 4.9
49 Major histocompatibility complex, class I, F HLA-F 3134 4.9
50 myosin, light chain kinase MYLK 4638 4.9
Down-regulated genes
1 extracellular link domain containing 1 XLKD1 10894 11.1
2 chemokine (C-C motif) ligand 14 CCL14 6358 11.0
3 ADAM metallopeptidase with thrombospondin type 1 motif, 18 ADAMTS18 170692 7.8
4 LIM domain binding 2 LDB2 9079 6.7BMC Medical Genomics 2009, 2:50 http://www.biomedcentral.com/1755-8794/2/50
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mutual relationship and differs in this aspect from Path-
way Analysis. GO analysis identified 21 categories of
genes to be significantly affected in HUVEC-K13-ERTAM
cells upon 4OHT treatment (Table 2). The GO categories
of immune response, cellular movement, inflammatory
disease, hematological system development, cancer and
cell-to-cell signaling were the statistically most over-repre-
sented, reflecting the predominance of chemokines and
cytokines among the K13-induced genes. Thus, both anal-
yses (by Pathway Analysis and by Ontology) were con-
cordant in the finding that cell signaling, immune
response and inflammation were the dominant categories
among the known affected functions of K13.
Confirmation of microarray results by a multiplex cytokine 
assay (Luminex) and comparative analysis of chemokines 
and cytokines induced by K13 and KSHV
The microarray data analysis suggested that expression of
a number of chemokines and cytokines genes was highly
induced following treatment of K13-ERTAM-expressing
HUVECs with 4OHT. In order to determine whether the
changes in the mRNA level results in a parallel increase in
the secretion of the cytokines and chemokines in the cel-
lular supernatants, we used a multiplex cytokine assay to
examine the secretion of cytokines and chemokines in the
supernatants of vector- and K13-ERTAM-expressing
HUVECs that had been either mock treated or treated with
4OHT for 48 hours. For comparison, we also included
supernatant from HUVECs that have been infected with
KSHV for 48 h. We selected the 48 h time point for the
comparative analysis as a qRT-PCR analysis revealed that
the transient increase in lytic gene expression seen imme-
diately following infection with KSHV returns to near
baseline level by this time point while the expression of
latent genes (e.g. K13 and LANA) is still maintained
(Additional File 5). As shown in Table 3, while 4OHT
treatment had no significant effect on the chemokine/
cytokine secretion by the control vector-expressing
5 keratin 18 KRT18 3875 5.3
6 dual specificity phosphatase 4 DUSP4 1846 5.3
7 ribonuclease, RNase A family, 1 (pancreatic) RNASE1 6035 4.7
8 periostin, osteoblast specific factor POSTN 10631 4.7
9 insulin-like growth factor binding protein 5 IGFBP5 3488 4.6
10 regulator of G-protein signalling 5 RGS5 8490 4.6
11 uroplakin 1B /// regulator of G-protein signalling 5 UPK1B 7348 4.5
12 regulator of G-protein signalling 4 RGS4 5999 5.5
13 Palmdelphin PALMD 54873 3.8
14 latent transforming growth factor beta binding protein 2 LTBP2 4053 3.2
15 C-X-C chemokine receptor type 4 CXCR4 7852 3.1
Table 1: List of most differentially regulated genes in 4OHT-treated K13 ER-HUVECs. (Continued)
Table 2: Gene Ontology of vFLIP K13 affected genes.
S. No. Molecular Function and Disease p-value Genes(n)
1 Immune Response 5.18E-22  1.76E-05 63
2 Cellular Movement 8.19E-19  1.83E-05 50
3 Inflammatory Disease 8.38E-16  1.22E-05 37
4 Hematological System Development and Function 8.94E-16  1.83E-05 53
5 Cancer 2.64E-15  1.83E-05 73
6 Cell-To-Cell Signaling and Interaction 3.71E-15  1.83E-05 47
7 Tissue Morphology 2.98E-14  9.68E-06 33
8 Immune and Lymphatic System Development and Function 2.68E-13  1.76E-05 44
9 Connective Tissues Disorders 3.99E-13  7.43E-06 21
10 Skeletal and Muscular Disorders 3.99E-13  7.43E-06 24
11 Cellular Growth and Proliferation 1.64E-12  1.45E-05 73
12 Cell death 1.27E-11  1.87E-05 52
13 Immunological Disease 2.47E-09  1.87E-05 32
14 Tissue Development 4.14E-11  1.76E-05 51
15 Cell Signaling 1.73E-10  7.56E-06 71
16 Cellular Development 3.41E-10  1.70E-05 32
17 Hematological Disease 4.29E-10  1.79E-05 39
18 Neurological Disease 2.34E-09  1.83E-05 8
19 Cell Cycle 4.54E-09  1.44E-05 7
20 Respiratory Disease 3.20E-08  1.61E-06 14
21 Viral Function 3.29E-08  3.29E-08 11BMC Medical Genomics 2009, 2:50 http://www.biomedcentral.com/1755-8794/2/50
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HUVECs, it significantly upregulated the secretion of sev-
eral chemokines and cytokines in the K13-ERTAM-express-
ing cells, thus confirming the microarray results. The
chemokines and cytokines whose expression was strongly
(≥10 fold) induced following 4OHT treatment of
HUVEC-K13-ERTAM  included IL-6 (10 fold), GM-CSF/
CSF2 (193 fold), MCP-1 (155 fold), CCL5/RANTES (36
fold), G-CSF/CSF3 (59 fold), CXCL10/IP-10 (149 fold)
and IL-12p40 (12 fold). Remarkably, all the above chem-
okines and cytokines, with the sole exception of CCL5,
were also induced in the supernatant from HUVECs that
had been infected with KSHV for 48 h. The cytokines/
chemokines with modest (2 to 9 fold) induction follow-
ing 4OHT treatment of K13-ERTAM HUVECs included IL-8,
TNFα, Eotaxin, MIP1α, IL-15, IFNα, MIG, IL-7, GROα,
and MCP-3. Again, all these cytokines/chemokines, with
the exception of TNFα and IL-15, showed more than 2
fold induction following KSHV infection. Taken collec-
tively, the above results provide further validation of our
microarray analysis and suggest that K13 plays a major
role in the upregulation of chemokines and cytokines
expression following KSHV infection.
K13 stimulates the promoter of CXCL10/IP-10 via NF- B 
activation
To study the mechanism by which K13 upregulates the
expression of chemokines, we selected CXCL10 as a repre-
sentative example. CXCL10 is a powerful chemoattractant
for T cells, monocytes/macrophages, NK cells and den-
dritic cells, and may contribute to the infiltration by
inflammatory cells in the KS lesions [24]. To investigate
the mechanism by which K13 upregulates CXCL10
expression, human embryonic kidney 293T cells were
transfected with a luciferase-based reporter construct con-
Table 3: Luminex-based multiplex cytokine assay showing the expression of chemokines and cytokines in the supernatants of HUVEC 
Vector and K13-ER cells with and without 4OHT treatment and following infection with KSHV.
Cytokines Vector 
Mock 
treated
Vector + 
4OHT
K13-ER-
Mock 
treated
K13-
ER+4OHT
KSHV Virus Fold change 
K13-ER
Fold change 
KSHV
Fold change 
based on 
Microarray 
data
IL-1b 155.5 193.5 148 200 200 1.3 1.3 1.07
IL-2 20 23 20 22 21 1.1 1.05 1.01
IL-4 15 15 16 23 17 1.4 1.06 -2.9
IL-5 5 5 4 7 5 1.75 1.25 1.2
IL-6 1946.5 2038 1043.5 10910 11242 10.45 10.77 21.17
IL-8 6115 6682 4459.5 10336 10094.5 2.31 2.26 31.5
IL-10 1023 985 1003 1011.5 1038.5 1.00 1.03 3.3
IFN-γ 24.5 20 21 31.5 27 1.5 1.28 1.9
CSF2 13 15 10 1938 51 193.80 5.10 15.1
TNF-α 8 10 9 24 14 2.66 1.55 5.6
EOTAXIN 5 6 4 10 6 2.50 1.50 3.4
MCP-1 3217 2928 85 13178 10235.5 155.03 120.41 71.4
MIP-1α 37.5 31 24 117 105 4.87 4.37 3.6
MIP-1β 38 43 42.5 65 58 1.52 1.36 1.4
CCL5 327 345.5 305.5 11126.5 197 36.42 0.644 48.3
EGF 8798 8695 8711 8962 8765 1.02 1.00 16.5
VEGF 421 491 466.5 479 447 1.02 0.95 2.3
FGF-β 415 428 515 615.5 500 1.19 0.97 10.7
G-CSF 95 104 36 2125 604 59.02 16.77 3.9
HGF 134.5 143.5 148.5 155.5 264 1.04 1.77 3.2
CXCL10 498.5 485.5 70 10453 2259 149.32 32.27 47.7
IL-12p40 21 18.5 16.5 197 34 11.93 2.06 97
IL-13 7 8 7 13 8 1.85 1.14 1.4
IL-15 11 12 10 39 12 3.90 1.20 7.8
IL-17 118 139 130 129 132 0.99 1.01 -1.3
IFN-α 56 60 40 131 98 3.27 2.45 1.4
MIG 13 12 14 39 37.5 2.78 2.67 3.8
IL-1α 454.5 521.5 469 752 494.5 1.60 1.05 2.3
IL-7 58 50 47 197 181.5 4.19 3.86 2.1
IL-1Rα 30 31 28.5 90 59.5 3.15 2.08 3.8
IL-2R 12 16 15 21.5 18 1.43 1.20 2.6
GROα 13 13 14 110 17 7.85 1.21 7.7
MCP-2 26.5 25 23 37 23 1.60 1.00 4.4
MCP-3 12 14 10 23 372 2.30 37.20 2.3BMC Medical Genomics 2009, 2:50 http://www.biomedcentral.com/1755-8794/2/50
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taining the CXCL10 gene promoter. While co-expression
of K13 strongly activated the CXCL10 promoters, vFLIP
MC159 from the molluscum contagiosum virus, which
resemble K13 in structure but lacks the ability to activate
the NF-κB pathway [10,25], failed to do so (Figure 3a).
The involvement of the NF-κB pathway in K13-induced
CXCL10 transcriptional activation was confirmed by
using an NF-κB-defective mutant of K13, K13-58AAA
[14], which failed to activate the CXCL10 promoter (Fig-
ure 3a). Furthermore, K13-induced CXCL10 promoter
activity was effectively blocked by two phosphorylation-
resistant mutants of IκBα (IκBα SS32/36AA and IκBαΔN)
(Figure 3b) that are known to block the NF-κB pathway
[10], and by treatment with chemical inhibitors of the NF-
κB pathway, including Bay-11-7082 [21], IKK inhibitor VI
[26], PS1145 [27] and arsenic trioxide [28] (Figure 3c).
Collectively, these results support the involvement of the
NF-κB pathway in K13-induced upregulation of CXCL10.
Differential modulation of lymphatic differentiation genes 
by K13 and KSHV
Kaposi sarcoma spindle cells, the neoplastic cells of the
lesion, express markers of lymphatic endothelium
[29,30]. KSHV infection of blood vascular endothelial
cells not only makes them acquire a spindle shaped phe-
notype but is also known to induce their differentiation
into lymphatic endothelial cells which is accompanied by
expression of PROX-1, a master regulator of lymphatic
development, and expression of lymphatic markers such
as VEGFR-3, Podoplanin and XLKD1/LYVE1 [7-9]. Since
ectopic expression of K13 in vascular endothelial cells
induces spindle cell transformation [21,22], we examined
whether K13 can also mimic the effect of KSHV infection
on lymphatic differentiation and induce the expression of
lymphatic markers in HUVECs. However, we found that
K13 down-regulated the expression of the lymphatic
marker gene XLKD1/LYVE1 by 11 fold and had no major
effect on the expression of other lymphatic markers, such
as PROX1, VEGFR-3, Podoplanin, and CD206 (Table 1).
We also used qRT-PCR to confirm the results of microar-
ray analysis. Consistent with the published results, infec-
tion of HUVECs with KSHV led to a significant increase in
the expression of XLKD1/LYVE1, VEGFR-3 and PROX-1,
while treatment of HUVECs-K13-ERTAM with 4OHT failed
to do so (Figure 4). Thus, K13 expression is not sufficient
to account for the induction of lymphatic differentiation
markers in HUVECs observed following KSHV infection.
Discussion
K13 is one of the few KSHV-encoded latent proteins and
is consistently expressed in the KS spindle cells, the hall-
mark of KS lesions [31]. Ectopic expression of K13 in
human vascular endothelial cells is sufficient to make
them acquire a spindle-shaped morphology that is associ-
ated with NF-κB activation and increased production of a
K13-induced NF-κB activity is critical for the activation of  CXCL10promoter Figure 3
K13-induced NF-κB activity is critical for the activa-
tion of CXCL10promoter. (a). Right panel: 293T cells 
were transfected with an empty vector, wild-type K13, K13-
58AAA or MC159 (250 ng/well) along with a CXCL10 pro-
moter-driven luciferase constructs (75 ng/well) and a pRSV/
LacZ (β-galactosidase) reporter construct (75 ng/well), and 
the reporter assay performed as described under the Materi-
als and Methods section. Left panel: Expression of the trans-
fected proteins in the cell lysates is shown by 
immunoblotting with an antibody against the Flag epitope tag. 
Tubulin blot shows equal protein loading. (b). Right panel: 
Dominant-negative mutants of IκBα (IκBαΔN and IκBαSS32/
36AA) block K13-induced CXCL10 promoter activity. 293T 
cells were transfected either with the indicated plasmids and 
reporter assay performed as described for Figure 3a. The 
amount of IκBα mutant plasmids (500 ng/well) was five times 
the amount of vector or K13 (100 ng/well) plasmid and the 
total amount of transfected DNA was kept constant by add-
ing empty vector. Left panel: Expression of the transfected 
dominant negative mutants of IκBα in the cell lysates is 
shown by immunoblotting with an antibody against IκBα. 
Tubulin blot shows equal protein loading. (c). 293T cells 
were transfected with an empty vector or a vector encoding 
K13 and subsequently treated with DMSO (vehicle) or the 
indicated compounds for 16 hours prior to cell lysis. 
Reporter assay was performed as described for Figure 3a.BMC Medical Genomics 2009, 2:50 http://www.biomedcentral.com/1755-8794/2/50
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number of genes known to be upregulated in KSHV-
infected cells [21,22]. In this study, we provide a compre-
hensive picture of global transcriptional changes induced
by K13 in HUVECs. Our results provide the starting point
for future detailed analysis of the K13-induced genes in
the pathogenesis of KS.
As K13-induced spindle cell transformation of HUVECs is
accompanied by their loss of proliferating potential, it is
not possible to generate stable cultures of long-term pro-
liferating HUVECs expressing K13 for the purpose of glo-
bal gene expression analysis. To circumvent this problem,
we took advantage of our previously characterized
HUVEC-K13-ERTAM model system in which the K13 activ-
ity is dormant in the absence of 4OHT treatment [21]. The
HUVEC-K13-ERTAM maintains their normal cobblestone
appearance and are indistinguishable from the control
vector-expressing cells in their appearance and growth
characteristics in the absence of 4OHT treatment. The lack
of leakiness in this system was further confirmed by our
microarray and qRT-PCR analysis, which revealed no sig-
nificant difference in the gene expression profile between
the vector and K13-ERTAM-expressing HUVECs in the
absence of 4OHT. While 4OHT treatment significantly
changed the expression of a number of genes in K13-
ERTAM cells, it had no major effect on gene expression in
the control vector cells, thereby confirming that that
4OHT treatment had no major effect on gene expression
on its own. Another advantage of the use of this inducible
model system is that allowed us to compare the effect of
K13 activity on gene expression in the same cell popula-
tion, thereby avoiding any artifacts due to cell-to-cell
(clonal) variation.
It has been proposed that KSHV infection plays a major
role in the recruitment of inflammatory cells to the KS
lesions by upregulating the expression of chemotactic
chemokines and, consistent with this notion, latent infec-
tion of vascular endothelial cells with KSHV has been
known to upregulate the expression of several cellular
chemokines, such as IL-8, GRO-1, MCP-1, NAP-2, CCL5/
RANTES and CXCL16 [32,15,21,18,33,22]. The chemok-
ines induced by KSHV infection, such as IL-8, have been
also postulated to contribute to neoangiogenesis charac-
teristic of KS lesions. Our analysis revealed that chemok-
ines were the most upregulated genes upon induction of
K13 activity in HUVECs, which is consistent with the pre-
vious studies [21,22] and two recent studies that were
published while this manuscript was under review
[34,35]. Notable chemokines genes whose expression was
increased significantly by K13 included CCL2 (71 fold),
CCL20 (53 fold), CCL5/RANTES (48 fold), CXCL10 (47
fold), CCL3 (33 fold), IL8 (31 fold), CX3CL1 (22 fold),
CXCL1 (7) and CXCL5 (13 fold). In addition, expression
of genes encoding a number of cytokines (e.g. IL1a, IL6,
IL15, IL32, CSF1, CSF2, CSF3 and EBI3) and TNF family
ligands (TNFSF13B and Lymphotoxin beta) was signifi-
cantly increased upon induction of K13 activity. Since
chemokines and cytokines collectively represented the
most upregulated genes in K13 expressing HUVECs, we
confirmed their increased secretion in the supernatant of
4OHT treated K13-ERTAM cells. More importantly, a com-
KSHV infection upregulates the expression of lymphatic markers but K13 fails to do so Figure 4
KSHV infection upregulates the expression of lymphatic markers but K13 fails to do so. HUVECs were infected 
with KSHV for the indicated time intervals and the expression of lymphatic markers LYVE-1, VEGFR-3 and PROX-1 was deter-
mined by qRT-PCR analysis. In parallel, the expression of the lymphatic markers was determined in HUVECs-K13-ERTAMand -
vector cells that had been left untreated or treated with 4OHT (50 nM) for 48 h. The experiment was performed as described 
in the Materials and Methods section.BMC Medical Genomics 2009, 2:50 http://www.biomedcentral.com/1755-8794/2/50
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parison with KSHV-infected cells revealed that ectopic
expression of K13 is sufficient to induce most chemok-
ines/cytokines that are induced by KSHV infection. Since
K13 is one of the few KSHV genes that are expressed in
latently-infected KS spindle cells, the above results sup-
port the hypothesis that K13, either alone or in combina-
tion with other viral genes, plays a key role in the up-
regulation of chemokines and cytokines and subsequent
recruitment of inflammatory cells to the KS lesions.
We observed significant upregulation of adhesion mole-
cules (e.g. ICAM-1, VCAM-1 and E-Selectin), MHC-I,
TAP1, TAP2 and tapasin upon induction of K13 activity,
which is consistent with recent reports [22,36]. Increased
expression of adhesion molecules on vascular endothelial
cells expression by K13 might synergize with chemokines
to promote the recruitment of inflammatory and blood
cells into KS lesions. On the other hand, increased MHC-
I expression has been postulated to ensure controlled viral
dissemination during latency by promoting cytotoxic T
lymphocyte (CTL) proliferation [36]. K13-induced upreg-
ulation of adhesion molecules and MHC-1 molecules
during natural infection with KSHV may be modulated by
concomitant expression of viral lytic proteins, such as the
K5 gene product and vIRF1, which have been shown to
down-regulate the expression ICAM-1 and MHC-I mole-
cules [36,37].
Infection with KSHV has been reported to contribute to
neoangiogenesis, another characteristic feature of KS
lesions, by upregulating the expression of several genes
involved in the control of vascular modeling and angio-
genesis, such as VEGF-A, VEGF-C, angiopoietin-related
protein 4, thrombomodulin, and matrix metalloprotein-
ase (MMP-1) [32]. The expression of VEGF-A, VEGF-C and
angiopoietin-related protein 4 was not significantly
increased, and expression of thrombomodulin was
decreased 2-fold upon induction of K13 activity. Addi-
tionally, the expression of tissue factor pathway inhibitor
2 (TFPI2), a gene which is a negative inhibitor of aberrant
angiogenesis associated with tumor development was
increased 5-fold by K13 [38]. However, the expression of
semaphorin 3C (SEMA3C) and TNF-alpha-induced pro-
tein 2 (TNFAIP2), two invasion and angiogenic factors
[39-41], was induced 2 and 21 fold upon activation of
K13 activity, respectively. Similarly, the expression of
matrix metallopeptidase 10 (MMP10 or Stromolysin 2),
an enzyme implicated in the breakdown of extracellular
matrix during tumor invasion, metastases and angiogen-
esis [42], was highly induced (11 fold) upon induction of
K13 activity. Finally, K13 activity strongly (21 fold)
induced the expression of TNF alpha-induced protein 6
(TNFAIP6, also known as TSG-6), a member of the Link
module superfamily that regulates extracellular matrix
remodeling and inflammatory response [43]. Thus, K13
activity may contribute to neoangiogenesis in KS lesions
via increased production of angiogenic factors, such as IL-
8, SEMA3C and TNFAIP2, and to invasion and metastases
by stimulating extracellular matrix remodeling through
increased production of MMP10 and TNFAIP6.
K13 strongly induced two stress response genes, cyclooxy-
genase-2 (COX-2) and manganese superoxide dismutase
(SOD2), which have been reported previously to be
strongly induced by KSHV infection [32]. COX-2 is an
angiogenic stress response gene that was recently shown
to facilitate latent KSHV gene expression and the estab-
lishment and maintenance of latency [44]. SOD2 plays an
important role against mitochondrial oxidative stress by
diminishing reactive oxygen species [45], and may pro-
mote survival of KSHV-infected cells. Furthermore, while
this manuscript was under review, an independent study
reported upregulation of SOD2 expression by K13 in vas-
cular endothelial cells, which correlated with decreased
intracellular superoxide accumulation and increased
resistance to superoxide-induced death [34]. Two other
anti-apoptotic genes, baculoviral IAP repeat containing 3
(BIRC3/cIAP2) and BCl2-related protein A1 (BCL2A1),
were also strongly upregulated upon induction of K13
activity in our study, and may contribute to the survival of
KSHV-infected cells.
The genes belonging to the interferon response pathway
represented another class of genes whose expression was
upregulated upon induction of K13 activity. Notable
genes in this class included interferon γ-inducible protein
30 (IFI30), 28 kDa interferon responsive protein
(IFRG28), interferon stimulated exonuclease gene 20 kDa
(ISG20), guanylate binding protein 1 (GBP1), interferon
induced transmembrane protein 1 (IFITM1), interferon
regulatory factor-1, -2 and -7, interferon-induced protein
35 (IFI35), interferon-induced protein with tetratricopep-
tide repeats 3 (IFIT3), interferon omega 1, interferon
induced with helicase C domain 1 (IFIHI), and interferon,
beta 1.
K13 is a powerful activator of the NF-κB pathway and oth-
ers and we have previously reported that K13-induced
upregulation of proinflammatory cytokines in vascular
endothelium cells is associated with NF-κB activation and
can be blocked by genetic and pharmacological inhibitors
of this pathway [21,22]. Consistent with the ability of K13
to activate NF-κB, most of the genes induced by K13 in the
present study are known targets of the NF-κB pathway
[46,47], including NFKBIA (IκBα), which is not only a
direct target gene of the NF-κB pathway but also a key neg-
ative regulator of this pathway. The involvement of the
NF-κB pathway in K13-induced transcriptional activation
of chemokine genes was further supported by our studies
using the CXCL10 promoters. It needs to be noted, how-BMC Medical Genomics 2009, 2:50 http://www.biomedcentral.com/1755-8794/2/50
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ever, that the transcriptional activation of genes is usually
complex and it is conceivable that NF-κB pathway cooper-
ates with other signaling pathways in the transcriptional
activation of some genes.
Finally, we observed that K13 also down-regulated the
expression of several genes in HUVECs. In contrast to the
upregulated genes, the down-regulated genes were diverse
and did not belong to particular functional class. Never-
theless, these genes are known to act as tumor suppressor
(e.g. ADAMTS18 and Periostin) [48,49], apoptosis-
inducer (e.g. insulin like growth factor binding protein 5)
[50], and regulator of vascular integrity (regulator of G-
protein signaling 5) [51], suggesting that their down-reg-
ulation by K13 may have a causal role in the pathogenesis
of KS lesions.
Conclusion
Our microarray and multiplex cytokine analyses demon-
strate that K13 activity may contribute to the upregulation
of a majority of genes induced in HUVECs that are latently
infected with KSHV. These results are consistent with the
notion that K13, a powerful NF-κB activator, is one of the
few KSHV genes that are expressed in latently-infected
cells. However, interestingly, K13, by itself, can not mimic
the effect of KSHV infection in inducing lymphatic repro-
gramming of blood vascular endothelial cells. Thus, lym-
phatic differentiation by KSHV may require
supplementation by other viral gene activities.
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